查詢結果分析
來源資料
相關文獻
- The Effects of Two Different Cisplatin-Based Chemotherapy Regimens on Advanced Non-Small Cell Lung Cancer
- 中晚期子宮頸癌放射線合併化學治療之近況
- Metastatic Urothelial Carcinoma of the Bladder with Lymph Node-only Metastasis Treated with M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) Has a Better Survival than GC (Gemcitabine and Cisplatin)
- Successful Treatment of a Bulky Seminoma in an Abdominal Undescended Testis: A Case Report
- Ifosfamide-Based Chemotherapy for Previously Treated Lung Cancer Patients
- Treatment of Ultra-High Risk Gestational Trophoblastic Disease by an EMA/CE Regimen
- The Experience of Combination of Chemotherapy and Surgery in Treatment of Advanced Nonseminomatous Germ Cell Tumor of the Testis
- Malignant Primary Extragonadal Germ Cell Tumors of Mediastinum--An Analysis of Clinical and Radiological Features in 15 Cases
- 非小細胞肺癌術前輔助性化學治療的經驗
- Radiation Therapy in Primary Central Nervous System Lymphoma
頁籤選單縮合
題名 | The Effects of Two Different Cisplatin-Based Chemotherapy Regimens on Advanced Non-Small Cell Lung Cancer=兩種不同的化學治療配方對末期非小細胞肺癌的療效探討 |
---|---|
作者 | 陳志弘; 楊政達; 張文震; 廖宗琦; 曹昌堯; | 書刊名 | 長庚醫學 |
卷期 | 22:2 1999.06[民88.06] |
頁次 | 頁220-226 |
分類號 | 415.468 |
關鍵詞 | 非小細胞癌; 化學治療; 反應率; 平均存活時間; Non-small cell lung cancer; Chemotherapy; Response; Median survival; |
語文 | 英文(English) |
中文摘要 | 背景:根據早期報告,許多以順鉑為主的不同的化療配方,被使用於末期非小細 胞肺癌病人身上,但在臺灣此種告較為缺乏。本研究評估以順鉑為主的兩種不同的化學治療 配方對末期非小細胞肺癌的療效以及毒性。方法:從 1995 年 2 月到 1998 年 4 月,以回 朔研究方式討論 44 位末期非小細胞肺癌病人。 其中 22 位接受 5-FU, Leucovorin, Etoposide, Cisplatin (FLEP) 配方; 另外 22 位接受 Cisplatin, Etoposide, Mitomycin (PEM) 配方。結果: 兩組病人的化學治療反應率皆為 13.6 %。平均存活時間在 FLEP 為 160 ± 30 天 (Median ± SD);在 PEM 為 263 ± 104 天。影響存活時間的因素 包括對化學治療有無反應以及不同的配方。結論:本研究較低的化學治療反應率,可能導因 於我們使用較低的順鉑劑量。接受 FLEP 配方的病人存活時間較長。 |
英文摘要 | Background:Many different cisplatin-based regimens have been used on advanced nonsmall cell lung cancer (NSCLC) in previous studies but there have been few such references in Taiwan. In this study, we evaluated the efficacy and toxicity of two different regimens including 5-Fluorouracil, Leucovorin, Etoposide and cisPlatin (FLEP) and cisPlatin, Etoposide and Mitomycin (PEM) in the treatment of patients with advanced NSCLC. Methods:We retrospectively analyzed the records of 44 patients with NSCLC who met the selection criteria from February 1995 through April 1998. All of them were confirmed, using histologic tests, that they were in advanced stages, i.e. stage Ⅲ B or Ⅳ. Twenty-two patients received FLEP and 22 patients received PEM. Results: Three patients with FLEP therapy and 3 patients with PEM therapy had partial response. No patient had complete response. The response rate was 13.6% in both groups, respectively. The median survival was 160 ± 30 (median+DS) days for patients with FLEP therapy and 263 ± 104 days for patients with FEM therapy. The factors that were associated with longer survival in all patients included response (Stable Disease vs Disease Progression p=0.004, Partial Response vs Disease Progression p=0.047) and regimen of chemotherapy (PEM vs FLEP p=0.008). The major clinically significant toxicity was myelosupression. Conclusion: The responses to regimens, FLEP and PEM, were how in our study groups that might be due to the low dose of cisplatin and etoposide in our regimens. The patients with response to chemotherapy and PEM therapy had longer median survival than those who underwent FLEP therapy. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。